



#61648

PATENT  
Customer No. 22,852  
Attorney Docket No. 03495-0217-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
)  
Schwartz et al. ) Group Art Unit: Not yet assigned  
)  
Application No.: 10/083,678 ) Examiner: Not yet assigned  
)  
Filed: February 27, 2002 )  
)  
For: MHC-I-RESTRICTED )  
PRESENTATION OF HIV-1 )  
VIRION ANTIGENS WITHOUT )  
VIRAL REPLICATION. )  
APPLICATION TO THE )  
STIMULATION OF CTL AND )  
VACCINATION *IN VIVO*; )  
ANALYSIS OF VACCINATING )  
COMPOSITION *IN VITRO* )

RECEIVED

JUL 30 2003

TECH CENTER 1600/2900

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents are attached.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: July 29, 2003

By: 

Deborah Katz

Reg. No. 51,863

Phone: (202) 408-4382

Fax: (202) 408-4400

E-mail: [deborah.katz@finnegan.com](mailto:deborah.katz@finnegan.com)



## INFORMATION DISCLOSURE CITATION

OMB No. 0651-0011

Atty. Docket No.	03495-0217	Appln. No.	10/083,678
Applicant	Schwartz et al.		
Filing Date	February 27, 2002	Group:	[Text]

RECEIVED  
JUL 30 2003  
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS						
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	WO 99/65871 ✓	Dec. 23, 1999	PCT			English
	WO 99/41360 ✓	Aug. 19, 1999	PCT			English

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
•	Buseyne, F., et al., MHC-I-restricted presentation of HIV-1 virion antigens without viral replication, Nature Medicine, vol. 7, pp. 344-349 (2001).
•	Demi, L., et al., Recombinant human immunodeficiency Pr55 <sup>gag</sup> virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies, vol. 235, pp. 26-39 (1997).
•	Gruber, A., et al., Dendritic cells transduced by multiply deleted HIV-1 vectors exhibit normal phenotypes and functions and elicit an HIV-specific cytotoxic T-lymphocyte response in vitro, Gene Therapy, vol. 96, pp. 1327-1333 (2000).
•	Lu, S. et al., Use of DNA Expressing HIV-1 and Noninfectious HIV-1 Particles to Raise Antibody Responses in Mice, Virology, vol., 209, pp. 147-154 (1995).
•	Lu, W. and Andrieu, J-M., In vitro human immunodeficiency Virus eradication by autologous CD8+ T cells expanded with inactivated-virus-pulsed dendritic cells, J. of Virol., vol. 75, pp. 8949-8956 (2001).
•	Marsac, D., et al., Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 gag particles, J. of Virol., vol. 76, pp. 7544-7553 (2002).
•	Rossio, J.L., et al., Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins, J. of Virol., vol. 72, pp. 7992-8001 (1998).
•	International Search Report for PCT/EP 02/02620, mailed June 30, 2003

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce